Biomarin awaits crucial approvals and flat growth in 2021
2021 could turn out to be an important year for Biomarin, which expects to get a growth hormone against dwarfism approved on the one hand, while battling health authorities in the US and the EU on the other, as the firm attempts to get approvals for its gene therapy against hemophilia.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
In 2020, Biomarin's revenue has increased from USD 1.7bn to USD 1.9bn, which is the highest revenue in the history of the still-growing US company.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab CEO: Three products may turn into five this year
For subscribers
.jpg&w=384&q=75)
